PACIRA BIOSCIENCES, INC. Impairment of Intangible Assets (Excluding Goodwill)
PACIRA BIOSCIENCES, INC. (PCRX) reported Impairment of Intangible Assets (Excluding Goodwill) of $25.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $25.87M.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2024-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2024-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $25.87M.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.87M derived: sum of 2 quarters · filed 2026-02-26 | $25.87M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $25.87M 10-Q · filed 2025-11-06 | $25.87M 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |